XORTX Therapeutics Inc.
XRTX
$0.88
-$0.02-2.22%
Weiss Ratings | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Good | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.99 | |||
Price History | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -1.12% | |||
30-Day Total Return | -24.78% | |||
60-Day Total Return | -28.70% | |||
90-Day Total Return | -42.48% | |||
Year to Date Total Return | -24.78% | |||
1-Year Total Return | -61.23% | |||
2-Year Total Return | -83.44% | |||
3-Year Total Return | -93.89% | |||
5-Year Total Return | -91.98% | |||
52-Week High % Change | -87.14% | |||
52-Week Low % Change | 5.88% | |||
Price | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $7.00 | |||
52-Week Low Price | $0.85 | |||
52-Week Low Price (Date) | Jan 15, 2025 | |||
52-Week High Price (Date) | Mar 07, 2024 | |||
Valuation | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 3.32M | |||
Enterprise Value | 1.18M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.04 | |||
Earnings Per Share Growth | -98.92% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 1.22 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $0.88 | |||
Enterprise Value/EBITDA (TTM) | -0.43 | |||
Enterprise Value/EBIT | -0.42 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 2.90M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 403 455 7727 | |||
Address | 3710 – 33rd Street NW Alberta Beach, AB T2L 2M1 | |||
Website | www.xortx.com | |||
Country | Canada | |||
Year Founded | -- | |||
Profitability | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -33.81% | |||
Return on Equity | -- | |||
Income Statement | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -2.76M | |||
EBIT (TTM) | -2.84M | |||
Net Income (TTM) | -736.60K | |||
Net Income Avl. to Common (TTM) | -736.60K | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 55.98% | |||
EPS Diluted (TTM) | -0.04 | |||
EPS Diluted Growth (Q YOY) | 69.82% | |||
Balance Sheet | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 2.30M | |||
Cash Per Share (Q) | $0.79 | |||
Total Current Assets (Q) | 2.41M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 2.13M | |||
Current Ratio (Q) | 6.216 | |||
Book Value Per Share (Q) | $0.73 | |||
Total Assets (Q) | 3.85M | |||
Total Current Liabilities (Q) | 387.80K | |||
Total Debt (Q) | 61.50K | |||
Total Liabilities (Q) | 1.72M | |||
Total Common Equity (Q) | 2.13M | |||
Cash Flow | XRTX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -44.70K | |||
Cash from Financing (TTM) | 1.36M | |||
Net Change in Cash (TTM) | -2.77M | |||
Levered Free Cash Flow (TTM) | -1.71M | |||
Cash from Operations (TTM) | -4.09M | |||